Cargando…
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of patients with locally advanced unresectable and metastatic non-small cell lung cancer (NSCLC). Now, ICIs are undergoing evaluation as neoadjuvant therapy in patients with early-stage, resectable NSCLC using c...
Autores principales: | Pradhan, Monika, Chocry, Mathieu, Gibbons, Don L., Sepesi, Boris, Cascone, Tina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867746/ https://www.ncbi.nlm.nih.gov/pubmed/33569339 http://dx.doi.org/10.21037/tlcr-20-573 |
Ejemplares similares
-
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
por: Huynh, Caroline, et al.
Publicado: (2021) -
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021) -
Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021) -
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021) -
Mediastinal staging for non-small cell lung cancer
por: Leiro-Fernández, Virginia, et al.
Publicado: (2021)